In the latest trading session, 2.25 million Summit Therapeutics Inc (NASDAQ:SMMT) shares changed hands as the company’s beta touched -1.06. With the company’s most recent per share price at $19.11 changed hands at -$3.01 or -13.61% at last look, the market valuation stands at $14.09B. SMMT’s current price is a discount, trading about -77.34% off its 52-week high of $33.89. The share price had its 52-week low at $2.10, which suggests the last value was 89.01% up since then.
Analysts gave the Summit Therapeutics Inc (SMMT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SMMT as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Summit Therapeutics Inc’s EPS for the current quarter is expected to be -0.06.
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Instantly SMMT was in red as seen in intraday trades today. With action -10.58%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 7.09%, with the 5-day performance at -10.58% in the red. However, in the 30-day time frame, Summit Therapeutics Inc (NASDAQ:SMMT) is -22.47% down.
The consensus price target for the stock as assigned by Wall Street analysts is 36, meaning bulls need an upside of 46.92% from its recent market value. According to analyst projections, SMMT’s forecast low is 23 with 45 as the target high. To hit the forecast high, the stock’s price needs a -135.48% plunge from its current level, while the stock would need to soar -20.36% for it to hit the projected low.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 1.2566% or 8.82 million shares worth $68.78 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology. With 3.43 shares estimated at $64.97 million under it, the former controlled 0.47% of total outstanding shares. On the other hand, Fidelity Select Portfolios – Biotechnology held about 0.38% of the shares, roughly 2.79 shares worth around $52.9 million.
